

Attorney Brent Wisner Tells RFK, Jr.: Drugmakers Knew Zantac Caused Cancer But Sold It Anyway for 40 Years

In an interview on 'RFK Jr. The Defender Podcast,' award-winning attorney Brent Wisner talked with Robert F. Kennedy, Jr. about litigation to hold Zantac manufacturers accountable.

By [Susan C. Olmstead](#)

Global Research, March 28, 2022

[Children's Health Defense](#) 25 March 2022

Region: [USA](#)

Theme: [Law and Justice](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch_crg](#) and Twitter at [@crglobalization](#). Feel free to repost and share widely Global Research articles.

The once widely used heartburn drug Zantac was the topic of a recent episode of the "[RFK Jr. The Defender Podcast](#)."

Robert F. Kennedy, Jr., chairman and chief legal counsel of [Children's Health Defense](#), interviewed Brent Wisner, an [award-winning](#) mass tort litigator with [Baum Hedlund Aristei & Goldman](#), who is representing plaintiffs who allegedly developed cancer after taking Zantac. The plaintiffs are suing the pharmaceutical companies that sold the drug.

Kennedy and Wisner are colleagues. They worked together during the landmark lawsuit [Dewayne Johnson v. Monsanto Company](#), the first Roundup cancer lawsuit to proceed to trial. The jury awarded groundskeeper Johnson \$289.2 million.

"Brent Wisner arguably is the best lawyer in the country," said Kennedy. "He's won every award that you can possibly win for litigation. He is a versatile lawyer and he's an extraordinary performer. He has a chemical link to jurors like I've never seen before."

Wisner is now working to hold accountable the makers of Zantac for allegedly concealing knowledge of a cancer-causing ingredient in the drug.

Zantac, an over-the-counter medication, was [withdrawn from the market](#) in 2020 when it was determined that it contained the human carcinogen N-nitrosodimethylamine (NDMA).

Now, pharmaceutical companies [GlaxoSmithKline, Sanofi, Pfizer and Boehringer Ingelheim](#)

are facing class-action lawsuits from people who developed cancer after taking the drug.

Wisner claims that the product was sold for decades with the knowledge that NDMA caused harm. He said,

“We’re talking 40 years they sold this product and they knew it. And we have the documents. ... I mean, we have documents where they straight up say, ‘this stuff causes this cancer.’”

Wisner explained:

“NDMA is a very, very potent human carcinogen discovered in the thirties, in the development of rocket fuel. And it literally has no purpose in our world, except for the fact that it causes cancer. It’s actually used in laboratory experiments to induce cancer in animals.

“It’s probably something that has caused an innumerable number of people’s cancers, because it was such a widely used product.”

The cancers that MDNA are more likely to cause include those of the bladder, liver and stomach, as well as colorectal cancer, prostate cancer and breast cancer, said Wisner.

“It’s a complex scientific inquiry, but we think that we have the science to really push those cancers forward,” he said. “And we’re litigating them actively right now in our proceeding in California, which is exciting.”

Kennedy pointed out that [people can still become plaintiffs](#) in the class-action lawsuit.

“If people who are listening to this podcast — or people who are friends or family of those who are listening to this podcast — have any of those kind of cancers and can show that they took Zantac for a period of time, they have an opportunity to ... become part of this litigation,” he said.

Wisner is confident the litigation will be successful, although he warned it will take some time.

“These things take many years and involve many, many thousands and thousands of people,” he said. “But, you know, we have a good track record of taking care of our clients like we did in the [Roundup litigation](#). And we’re planning to do the same here.”

A California state court judge [has scheduled](#) the first Zantac trial to take place on Oct. 10.

[Watch the podcast here](#) or click the image below.



*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @globalresearch_crg and Twitter at @crglobalization. Feel free to repost and share widely Global Research articles.

Susan C. Olmstead is the assistant editor of The Defender.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Susan C. Olmstead](#), [Children's Health Defense](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Susan C. Olmstead](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long as the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca